This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


reputable news agency


JN.1 variant now behind nearly half of US COVID cases

JN.1 variant now behind nearly half of U.S. COVID cases

As Americans travel far and wide to see family and friends this holiday season, a new COVID variant named JN.1 has become dominant across the country.

A descendant of the BA.2.86, JN.1 now accounts for 44 percent of COVID cases, up from roughly 7 percent in late November, the latest data from the U.S. Centers for Disease Control and Prevention shows.

"Variants take some time to get going," Dr. William Schaffner, an infectious disease specialist at Vanderbilt University Medical Center, told the New York Times. "Then they speed up, they spread widely, and just when they're doing that, after several months, a new variant crops up."

The is likely fueling the rise of JN.1, he added.

"When people are gathered inside close to each other, having parties and traveling and the like, those are the kind of circumstances where all respiratory viruses, including JN.1, have opportunities to spread," Schaffner said.

Still, the speed at which the JN.1 variant has spread this month suggests it may spread more easily and be better at evading people's immune systems than other circulating variants, according to a recent CDC report.

"It is too early to know whether or to what extent JN.1 will cause an increase in infections or hospitalizations," the CDC said in its report.

Luckily, JN.1 does not seem to be causing more yet, Schaffner noted.

The other good news? The updated COVID vaccines that were released in September produce antibodies that work against JN.1, which is distantly related to the XBB.1.5 variant the tweaked vaccines target.

"For those who were recently infected or boosted, the cross-protection against JN.1 should be decent, based on our laboratory studies," Dr. David Ho, a virologist at Columbia University in New York City, told the Times.

Ho led research published on the preprint server bioRxiv in early December that showed the latest COVID vaccines produce a strong antibody response to JN.1.

Despite the fact that JN.1 may not cause more than other variants, hospitalizations have started creeping up recently, the Times reported.

For the week of Dec. 10, there were just under 26,000 COVID-linked hospitalizations, a 10 percent increase from about 23,000 hospitalizations the week before. However, those numbers are still far lower than they were during during the peak of the tripledemic last winter, when COVID, flu and R.S.V. cases all surged simultaneously.

JN.1 will most likely remain the dominant COVID variant through spring, Schaffner said.

How can you protect yourself?

Experts said everyone should consider getting vaccinated, especially those who are over 65, are immunocompromised, have that put them at higher risk of severe illness or are visiting loved ones who may be vulnerable.

"Give yourself a New Year's present by getting this vaccine if you haven't done it yet," Schaffner said.

More information: Visit the CDC for more on COVID.

Copyright © 2023 HealthDay. All rights reserved.

Citation: JN.1 variant now behind nearly half of US COVID cases (2023, December 29) retrieved 24 May 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Rising COVID hospitalizations, new variants have Americans on edge


Feedback to editors